Best Practices and Research Advances in Thoracic Oncology: A Regional Series SE Asia Course 1: Liquid Biopsy in Lung Cancer-Adequate Technology for Liquid Biopsy

Video Transcription

Video Summary

Dr. Aaron Tan, a medical oncologist, discussed advancements in liquid biopsy technology at the IASLC webinar. He drew parallels to the infamous Theranos case to illustrate the importance of adequate technology, especially in lung cancer diagnostics. Liquid biopsy, a non-invasive technology focused primarily on circulating tumor DNA (ctDNA), is gaining traction for molecular profiling, minimal residual disease (MRD) assessment, and monitoring treatment response in non-small-cell lung cancer (NSCLC). Tan highlighted different assays like NGS and ddPCR, which offer varying sensitivities for different cancer stages. He emphasized the significance of personalized panels and technological innovations in enhancing detection accuracy and managing early-stage lung cancer. The talk also covered ctDNA's role as a dynamic response marker in advanced lung cancer therapy. Dr. Tan stressed the importance of understanding underlying technology and cost-effectiveness for clinical applications to facilitate real-world implementation.

Asset Subtitle

Aaron C. Tan, MBBS, PhD

Keywords

liquid biopsy

circulating tumor DNA

lung cancer diagnostics

molecular profiling

personalized panels